Table 2 Cox regression analysis for risk factors for treatment modification due to toxicity in patients started on standard antiretroviral first line regimen at the Infectious Diseases Institute

Gender

 Male

Ref

0.15

Ref

0.67

 Female

1.08 (0.98–1.19)

1.03 (0.89–1.19)

Age, per 5 years increase

1.13 (1.10–1.16)

< 0.001

1.14 (1.11–1.18)

< 0.001

WHO stage

 1 and 2

Ref

Ref

0.002

 3 and 4

1.48 (1.33–1.64)

< 0001

1.19 (1.06–1.34)

BMI kg/m²

 Underweight (< 18.5)

Ref

Ref

 Normal (18.5–25)

0.73 (0.64–0.83)

< 0001

0.79 (0.69–0.91)

0.001

 Overweight (> 25)

0.71 (0.61–0.83)

< 0.001

1.92 (0.78–1.09)

0.334

CD4 count

 < 200 cells/μL

Ref

Ref

 200–350 cells/μL

0.73 (0.65–0.83)

< 0001

0.81 (0.71–0.93)

0.002

 > 350 cells/μL

0.51 (0.45–0.58)

< 0.001

1.09 (0.89–1.34)

0.386

ART regimen (N, %)

 Stavudine

Ref

Ref

 Zidovudine

0.44 (0.39–0.48)

< 0001

0.51 (0.44–0.59)

< 0001

 Tenofovir

0.16 (0.14–0.20)

< 0001

0.17 (0.14–0.22)

< 0001